Bioness Israel (a Bioventus Rehab Company)

bioness.com (under construction) ; www.bioventus.com/products/restorativetherapies

Formerly NESS - Neuromuscular Electrical Stimulation Systems

Multinational Corporation

TECH VERTICALS

Healthtech, Life Sciences, Medical Devices, MedTech, Neurostimulation

General Data

Sector	Medical Devices
Established	2007
Number of Employees	25
Reg. Number:	abCDe

DESCRIPTION

Bioness, a Bioventus Rehab Company, develops functional electrical stimulation systems, robotic systems and software therapy programs that provide functional and therapeutic benefits for individuals affected by central nervous system disorders and orthopedic injuries.

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing.

TECHNOLOGY

H200 Wireless Hand Rehabilitation System, L300 Foot Drop System, L360 Thigh System, Vector Gait & Safety System, Functional Electrical Stimulation (FES), Integrated Therapy System.

Products and Phases

Product	Phase
L300 Go	FDA Approved CE Approved
The new L300 Go improves key features of Bioness award winning functional electrical stimulation (FES) foot drop and thigh weakness devices to provide unmatched freedom and independence for people recovering from Stroke, Multiple, Sclerosis, Cerebral Palsy, Traumatic Brain Injury, or Incomplete Spinal Cord Injury.

	TARGET MARKETS
	Patients with central nervous system disorders and orthopedic injuries.

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
		Bioventus
B695093E-207A-E111-AC59-00155D32A403	R&D Center	Bioness Israel (a Bioventus Rehab Company)	Bioventus

REMARKS

Date	Remark
01/10/2024	Bioventus signed a definitive agreement to sell Bioness to Accelmed Partners for up to $45m.
30/03/2021	Parent Company, Bioness Inc., was acquired by Bioventus Inc. for $45 million in up-front consideration, with up to $65 million of contingent consideration related to the achievement of certain key milestones.
01/06/2009	ATAC announced the cancellation of the reverse merger. ATAC will be liquidated.
01/12/2008	Advanced Technology Acquisition Corp. (ATAC), a blank check company (Amex: AXC), announced its intention to merge with Bioness Inc.
01/06/2007	Bioness Inc. acquired NESS and turned it into its Israeli R&D center.

CONTACT INFO

Expand / Collapse All

Main Address: Hod Hasharon, Israel

Address	8 Hanagar St
POB	7304
City	Hod Hasharon
Country	Israel
Zip	4501309

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Dror Harel Zion	General Manager
Ms. Pazit (Yohai) Oslerne	Finance Manager

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Other

Jun. 15, 2007

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Venture Capital Fund	abCDe	Original investment was in Ness. During 2010 Teuza sold a part of its holdings in the company to Alfred Mann for $2.8m. During 2012 it sold 1.5% of its shares to Alfred Mann for $3.3m. 12/2014: Received share options in exchange for MoniTel shares. 2019: Held 2.2% of the company. 03/2021: All holdings sold due to acquisition of Parent company, Bioness Inc.

Last Updated:	abCDe
IVC Number:	abCDe